HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Abstract
Purpose: Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction of HER2-overexpressing (HER2+) breast cancers escape from these drug combinations. In this study, we sought to discover the mechanisms of acquired resistance to the combination of lapatinib + trastuzumab.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 01, 2017
- Source ID
- 10.1158/1078-0432.ccr-16-2287
Entities
People
- Ariella B. Hanker
- Carlos L Arteaga
- Christos Sotiriou
- David F. Brown
- David Venet
- Emma Langley
- Eric Sanford
- Garrett M Frampton
- Heikki Joensuu
- James P. Koch
- Jan C. Brase
- Jennifer Becker
- Jens Huober
- Joan T. Garrett
- Josep Baselga
- M. Reid Groseclose
- Martine Piccart
- Mónica Valeria Estrada
- Paula González Ericsson
- Philip Owens
- Phillip S. Kim
- Preston D. Moore
- Samira Majjaj
- Sharat Singh
- Stephen Castellino
- Sylvain Brohée
Organizations
- American Cancer Society
- GSK
- Helsinki University Central Hospital
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- National Institutes of Health
- Ulm University
- United States Department of Defense
- Université Libre de Bruxelles
- Vanderbilt University
- Vanderbilt-Ingram Cancer Center